DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The "Hyperparathyroidism - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Hyperparathyroidism development.The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

ClinicalNon-clinicalInactive: Discontinued and/or Dormant

Scope

The report provides a snapshot of the pipeline development for HyperparathyroidismThe report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for HyperparathyroidismThe report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical informationProvides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for HyperparathyroidismThe report also covers the dormant and discontinued pipeline projects related to HyperparathyroidismCompanies FeaturedAmgen Inc.Deltanoid Pharmaceuticals Inc.Mitsubishi Tanabe Pharma Corp.OPKO Health Inc.Shire PLC

Key Topics Covered

1. Report Introduction

2. Hyperparathyroidism Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Hyperparathyroidism

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name: Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name: Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

7. Therapeutic Assessment

Assessment by Route of AdministrationAssessment by Stage and Route of AdministrationAssessment by Molecule TypeAssessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name: Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9f7j9f/hyperparathyroidis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180907005275/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs ,Endocrine and Metabolic Disorders Drugs

KEYWORD: UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/07/2018 10:10 AM/DISC: 09/07/2018 10:10 AM

http://www.businesswire.com/news/home/20180907005275/en